"As a multi-hyphenate scientist, entrepreneur, and once-inventor of the world's smallest computer, Betts-LaCroix is excited by paradigm change. At the helm of what is essentially Altman's playground for experimenting with pushing the limits of the human lifespan, Betts-LaCroix is hoping to engineer the same shift that air conditioning brought to hot summer days for your brain and body. Ideally, one day, decouple aging from decline and disease."
"Retro is set to start its first clinical trial since its launch in 2021, with an initial $180 million investment from Altman. Betts-LaCroix told Business Insider that by the end of 2025, Retro will have dosed its first trial patient with an experimental pill called RTR242. It's designed to help reverse Alzheimer's by reviving autophagy. This cellular recycling process in our body - the same one that's triggered by fasting - often goes haywire in old age, and is widely thought to have broad antiaging effects."
Retro Biosciences launched in 2021 with an initial $180 million investment from Sam Altman and aims to decouple aging from decline and disease. The company plans to begin its first clinical trial and expects to dose its first patient with experimental pill RTR242 by the end of 2025. RTR242 is intended to revive autophagy, a cellular recycling process that falters with age and is implicated in Alzheimer's and broader aging-related decline. Retro has selected an Australian Phase 1 site, chosen lab vendors, plans enrollment toward year-end, and seeks a $1 billion Series A for larger trials.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]